Serum level of IL-17 in patients with multiple myeloma and its clinical significance.
- Author:
Xiu-Lian ZHANG
1
;
Wei-Hua ZHANG
;
Xing-Huo FAN
;
Fang WEI
;
Miao ZHANG
Author Information
1. Department of Hematology, First Hospital of Shanxi Medical University, Taiyuan, China. zxlsj@126.com
- Publication Type:Journal Article
- MeSH:
Adult;
Aged;
Aged, 80 and over;
Case-Control Studies;
Female;
Humans;
Interleukin-17;
blood;
Male;
Middle Aged;
Multiple Myeloma;
blood;
pathology;
Neoplasm Staging;
Prognosis
- From:
Journal of Experimental Hematology
2012;20(4):930-932
- CountryChina
- Language:Chinese
-
Abstract:
This study was purposed to detect the serum concentrations of interleukin-17 (IL-17) in patients with multiple myeloma (MM), and to investigate its clinical significance. the serum IL-17 levels in 33 patients with MM and 20 normal control subjects were quantified by using double antibody sandwich ELISA, and serum β2-microglobulin (β2-MG) levels were detected by radioimmunoassay. The results showed that the serum concentrations of IL-17 and β2-MG in patients with MM were significantly higher than those in the control group (P < 0.001), the serum concentrations of IL-17 and β2-MG in active stage were significantly higher than those in stable stage (P < 0.05), the serum concentrations of IL-17 and β2-MG were significantly higher in stage III than that in stage II according to International Staging System (ISS) (P < 0.05), the serum IL-17 and β2-MG levels were significantly correlated (r = 0.690, P < 0.05). It is concluded that the serum IL-17 level correlates with active/stable stages of MM and staging of MM, IL-17 may play an important role in development stage and prognosis of this disease.
